$NBTX

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) presented Phase 1 study results showing 41.7% ORR and 17.8-month median survival in 24 advanced melanoma patients treated with JNJ-1900 (NBTXR3) and immunotherapy. The treatment demonstrated an acceptable safety profile and potential immune activation, warranting further trials. Data were shared at the 2026 ESMO Congress.

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) appointed Arnd Christ as CFO, effective October 1, 2026. Christ succeeds Bart Van Rhijn, who served for five years. Christ has over 25 years of experience in biotech finance, including roles at Immatics N.V. and other companies. The company is a late-stage clinical biotechnology firm focused on cancer and other major diseases.

Guggenheim initiated coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target, focusing on its JNJ-1900 partnership with Johnson & Johnson (JNJ). The NANORAY-312 Phase 3 trial, evaluating JNJ-1900 in head and neck cancer, is expected to report final data in 2027. Guggenheim sees high odds of success, but the trial remains a key risk.

Nanobiotix SA ADR (NBTX) reported H1 2026 revenue of €5.6M, a net loss of €34.3M, and €110.9M in cash, funding operations into 2029. Phase 1 data for JNJ-1900 in NSCLC showed 79% 1-year locoregional control, 61% LPFS, and 70% OS, with no Grade ≥3 events. Phase 2 dose set at 33% GTV.

Nanobiotix S.A. (NBTX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 NANOBIOTIX Provides First Half 2026 Operational and Financial Update Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoreg

Nanobiotix (NBTX) reported 79% one-year locoregional control in a Phase 1 study of NBTXR3 with repeat radiation for inoperable lung cancer. All 24 patients completed treatment with no product-related severe adverse events, but eight had Grade 3 and two had Grade 5 radiation-related events. The study's small size and lack of control group limit conclusions.

Tom Lee of Fundstrat told CNBC on June 9 that market jitters are tied to the run-up to SpaceX’s $75 billion Nasdaq 100 IPO and ongoing tech capital raises, but he views consolidation as healthy. The article screens small caps with 5-year sales growth >30% and lists 12 hedge-fund favorites (data June 15), including Nanobiotix (€42.1m cash; €86.1m follow-on) and Agilon (Barclays $81; Benchmark $95).

Nanobiotix reported its voting rights as of May 31, 2026: 50,807,903 shares outstanding, with 54,304,858 total theoretical voting rights and 54,282,740 exercisable voting rights. The filing cites French Commercial Code L.233-8 II and AMF rules on gross and net voting-right calculations, relevant for threshold monitoring on Euronext Paris and Nasdaq.

Nanobiotix said it has been added to Euronext’s Tech Leaders segment and Tech Leaders Index, a Euronext initiative launched in 2022 to boost visibility of European high-growth technology firms with international investors. The company, a late-clinical biotech focused on physics-based nanotherapeutics, is listed on Euronext Paris and Nasdaq.

Nanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).